Search
Istradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigational[A184067] This region of the brain is highly involved in motor control.[A184067] Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease. … Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy.
Categories: Adenosine A2 Receptor Antagonists, Purinergic P1 Receptor AntagonistsHypercholesterolemia, Autosomal Dominant
go.drugbank.com/conditions/DBCOND0037437Synonyms: LDL receptor disorder, LDL - Low density lipoprotein receptor disorderDevafidugene civaparvovec
go.drugbank.com/drugs/DB16790InvestigationalDevafidugene civaparvovec is an investigational _in vivo_ genome editing product. … Developed by Sangamo Therapeutics, Inc., devafidugene civaparvovec is being investigated for the treatment of mucopolysaccharidosis Type I (MPS I).[L46716]
CX-717
go.drugbank.com/drugs/DB05047IllicitInvestigationalCX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.
Crofelemer
go.drugbank.com/drugs/DB04941ApprovedInvestigationalCrofelemer, previously known as the investigational drug SP-303, is a novel proanthocyanidin purified from the bark latex of the Amazonian Croton tree <i>Croton lechleri</i>. … It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.
Categories: Compounds used in a research, industrial, or household settingBasiliximab
go.drugbank.com/drugs/DB00074ApprovedInvestigationalA recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also … It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes
Categories: Interleukin-2 Receptor Antagonist, Interleukin-2 Receptor Blocking AntibodyDexchlorpheniramine maleate
go.drugbank.com/drugs/DB09555ApprovedDexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine. … Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.
Darunavir
go.drugbank.com/drugs/DB01264ApprovedInvestigational[L9227] As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy.[A2278,A2281] It was initially approved by the FDA in 2006. … [L9227] Darunavir is being studied as a possible treatment for SARS-CoV-2, the coronavirus responsible for COVID-19, due to in vitro evidence supporting its ability to combat this infection.
Categories: Antivirals used in combination for the treatment of HIV infectionsCyclobenzaprine
go.drugbank.com/drugs/DB00924ApprovedInvestigational[A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury. … [A184982] It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.
Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor AntagonistsTeriflunomide
go.drugbank.com/drugs/DB08880ApprovedInvestigationalTeriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. … It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms.